Contingency Management for Cannabis Use for Persons With HIV

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-01

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the feasibility and impact of 28-days of monitored abstinence from cannabis use on symptoms of depression and anxiety, pain, sleep, cannabis use withdrawal, HIV viral load and biomarkers of systemic inflammation among PLWH and who use cannabis regularly (weekly or more often). This will be a single arm pilot feasibility trial involving a contingency management program to induce cannabis abstinence. Specifically, the contingency management program will provide motivational (monetary) incentives to participants who achieve biochemically verified cannabis abstinence. Over the 28-days of this pilot feasibility trial, participants will attend seven study visits. During these visits, participants will complete survey questionnaires to assess sociodemographic, psychosocial, and behavioral factors. In addition, participants will provide blood and urine specimens for testing and quantitation of HIV viral load, biomarkers of systemic inflammation and for the detection of cannabis and other drugs of abuse.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Reducing Co-occurring Substance Use and HIV Risk Among Stimulant-using Men at High Risk for HIV in the United States of America.

NCT07281378

Drug Use Disorders PrEP Uptake PrEP Adherence +1 more

NOT_YET_RECRUITING NA

Consequences of Marijuana Use in HIV-infected Youth

NCT03927053

Youth With HIV

COMPLETED

Contingency Management in HIV Care for Both Stimulant Use & ART Adherence

NCT06564792

Stimulant Use (Diagnosis) Hiv

COMPLETED NA

Contingency Management for PrEP Adherence and/or Methamphetamine Use

NCT04563962

Methamphetamine-dependence HIV-1-infection

COMPLETED NA

Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women

NCT03633721

HIV AIDS Aging

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Marijuana HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Contingency Management - Cannabis

Participants will be incentivized following biochemical verification (from urine samples) of cannabis abstinence.

Group Type EXPERIMENTAL

Contingency Management - Cannabis

Intervention Type BEHAVIORAL

Participants in the contingency management program will be provided financial incentives for 28-days of cannabis abstinence. At every visit, participants will provide urine samples for the biochemical verification of cannabis abstinence). Participants with evidence of cannabis abstinence will be provided a financial incentive that increases across subsequent study visits.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Contingency Management - Cannabis

Participants in the contingency management program will be provided financial incentives for 28-days of cannabis abstinence. At every visit, participants will provide urine samples for the biochemical verification of cannabis abstinence). Participants with evidence of cannabis abstinence will be provided a financial incentive that increases across subsequent study visits.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV-positive (confirmed via HIV medication or relevant HIV labs in subject's name)
* Self-report of cannabis use at least once per week in the 6-month period prior to consent
* Provide a positive urine toxicology (UTOX) screen for cannabis
* Not seeking treatment for cannabis use
* Willing to stop using cannabis for 28 days and attend eight study visits over six weeks.
* Ability and willingness to provide inform consent
* English fluency

Exclusion Criteria

* Currently receiving treatment for cannabis or other drug use disorder
* Diagnosed or receiving treatment for a current major depressive or anxiety disorder
* Diagnosed with any current alcohol or substance use disorder (excluding nicotine) using the Structured Clinical Interview for Clinical Disorders (SCID) Interview (22)
* Positive UTOX screen for opioids
* Having a medical, psychiatric, occupational, or other condition that, in the judgment of the study physician, would make participation difficult or unsafe.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No